Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
The Trump administration is touting massive projected savings from its still-secret drug pricing deals, though outside experts say there’s little way to independently verify the math.
Also, FDA leadership is facing fresh accusations of political interference in drug reviews, AI oncology startups are trying to make cancer care virtual, and scientists are opening up an entirely new frontier of biology hidden inside the “dark proteome.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
<
Leave a Reply